A Phase 1 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Combination With Toripalimab in Patients With Advanced Solid Tumors
Latest Information Update: 04 Apr 2024
Price :
$35 *
At a glance
- Drugs MAX-40279 (Primary) ; Toripalimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Maxinovel Pharmaceuticals
- 16 May 2022 New trial record